Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Dinaciclib in Hematologic Malignancies
NCT02684617Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2016
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, open-label trial of dinaciclib and pembrolizumab in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) (3 cohorts), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicity at 42 days, Adverse Events at 582 days and 1 more. Started Mar 2016; status: terminated.
02
Drugs
dinaciclibpembrolizumab
03
Conditions
chronic lymphocytic leukemia (CLL)multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02684617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684617.